CLINICALLY ADJUSTED VERSUS THERAPEUTIC DRUG MONITORING DOSING REGIMENS WITH ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM THE SERENE-CD MAINTENANCE STUDY

Silvio Danese  ¹     William Sandborn  ²     Edward V. Loftus Jr.  ³     Stephen B Hanauer  ⁴     Stefan Schreiber  ⁵     Laurent Peyrin-Biroulet  ⁶     Remo Panaccione  ⁷     Julian Panés  ⁸     Filip Baert  ⁹     Jean-Frédéric Colombel  ¹⁰     Marc Ferrante  ¹¹     Edouard Louis  ¹²     Alessandro Armuzzi  ¹³     Sasikiran Goteti  ¹⁴     John Liu  ¹⁴     Nael M. Mostafa  ¹⁴     Thao Doan  ¹⁴     Joel Petersson  ¹⁴     Anne M. Robinson  ¹⁴     Alexandra Song  ¹⁴     Geert R. D'Haens  ^15    
1 Humanitas Research Hospital, Rozzano, Italy
² University of California San Diego, La Jolla, United States
³ Mayo Clinic, Rochester, United States
⁴ Feinberg School of Medicine, Northwestern University, Chicago, United States
⁵ Universität Kiel UKSH, Kiel, Germany
⁶ Nancy University Hospital Inserm U954 Department of Hepato-Gastroenterology, Vandoeuvre les Nancy, France
⁷ University of Calgary, Calgary, Canada
⁸ Hospital Cli­nic Barcelona, Barcelona, Spain
⁹ Az Delta, Roeselare, Belgium
¹⁰ Icahn School of Medicine at Mount Sinai, New York, United States
¹¹ University Hospitals Leuven, Leuven, Belgium
¹² University Hospital of Liège, Liège, Belgium
¹³ Complesso Integrato Columbus Catholic University, Rome, Italy
¹⁴ AbbVie, North Chicago, United States
¹⁵ AMC Amsterdam Inflammatory Bowel Disease Centre, Amsterdam, Netherlands

Topic
Gut Microbiota, IBD, Immunology

Session
IBD: Drug monitoring

Conference
UEG Week Virtual 2020

Citation
United European Gastroenterology Journal 2020; 8 (Supplement 1)